Leading HPAPI Manufacturing Companies

High potency active pharmaceutical ingredients act as a driving force behind innovative therapeutics, delivering potency in treating health challenges and navigating healthcare domain to new heights. We analyzed more than 150 companies that are actively engaged in engaged in offering contract manufacturing services for HPAPI and cytotoxic drugs. In this article, discover the top 5 HPAPI manufacturing companies.

High potency APIs represent a class of substances that elicit therapeutic effects at low doses; these compounds play a significant role in the development of drugs that address complex indications, such as autoimmune disorders, oncological disorders and some infectious diseases. Further, they selectively interact with specific targets involved in disease mechanism (offering an effective pharmacological response) and reduce the occurrence of side effects (enhancing patient safety).

However, the high potency manufacturing process is associated with certain challenges; some of which include requirement of specialized facilities (for containment and preventing cross contamination), advanced equipment (for purification of the final product) and stringent safety measures (for protecting both workers and environment). Therefore, outsourcing of HPAPI manufacturing to contract service providers emerged as a lucrative option for stakeholders in this domain in order to overcome the existing concerns; further, it enables access to experienced teams and sophisticated production units, thereby streamlining the manufacturing operations and reduce capital expenditures.

It is worth mentioning that the HPAPI manufacturing market is anticipated to witness substantial growth in the coming years, owing to the increasing prevalence of chronic conditions (demanding need for precision medicines, oncology drugs and targeted therapeutics), rising investments in drug development (enhancing therapeutic efficacy) and ongoing technological advancements (developing innovative containment strategy and containment solutions).

Roots Analysis has conducted an exhaustive study on Cytotoxic Drugs and HPAPI Manufacturing Market featuring the current market landscape of companies engaged in offering high potency manufacturing and cytotoxic drug manufacturing, and future opportunity associated with the cytotoxic drugs and HPAPI manufacturing market, till 2035.

Table of Contents

Below, we have listed (in alphabetical order), the top 5 HPAPI manufacturing companies:

1. Catalent
2. CARBOGEN AMCIS
3. Piramal Pharma Solutions
4. Pfizer CentreOne
5. STA Pharmaceutical (a WuXi AppTec company)

Interested in exploring all 150+ HPAPI manufacturing companies across various regions?

In this Article, Discover the Details on Top 5 HPAPI Manufacturing Companies

This article highlights the top 5 players to watch out for in this industry. These companies were chosen based on the number of manufacturing facilities. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

With More Than 20 Years of Experience in the High Potency Drugs Market, Catalent Claims to Possess the Capability to Handle Over 300 Potent Molecules Belonging to Category 3 and 4

Catalent is engaged in offering development solutions and advanced delivery technologies for drugs and biologics. It is worth mentioning that the company was founded in April 2007, post the acquisition of Pharmaceutical Technologies and Services segment of Cardinal Health by The Blackstone Group. As per the firm’s website, at any given time, over 1,000 products are being developed. Further, the company has enabled the acceleration of more than 1,000 partner programs and launched over 150 innovative products, annually.

By leveraging its extensive scientific expertise, the firm further provides integrated development, manufacturing, analytical, clinical supply and packaging solutions for highly potent molecules, including hormones and cytotoxic drugs. In addition, with a focus on operational and quality excellence, the company intends to make investments in growth-enabling capacity and capabilities. Interestingly, in December 2024, the company got acquired by Novo Holdings for an enterprise value amounting to approximately $ 16.5 billion.

HPAPI and Cytotoxic Drug Manufacturing Service Offerings:

Parameter	Description
Overview of HPAPI and Cytotoxic Drug Offerings	HPAPIs / Cytotoxic Drugs Production: The firm has set up a Center of Excellence for highly potent active pharmaceutical ingredients in Somerset, US. Additionally, it claims to have well trained personnel, special protocols and detailed risk assessment processes for safe handling and containment of high potency drugs. Conjugation Services: The company utilizes its SMARTag technology platform (initially developed by Redwood Bioscience) in order to produce optimized antibody drug conjugates and bioconjugates, having better stability and safety profiles. The technology offers site-specific, controlled drug-protein conjugation and employs naturally occurring modifications to proteins, which require minimal cell-line engineering. The company also produces stable conjugates by using its proprietary conjugation chemistry, which involves the incorporation of covalent carbon-carbon bonding. The firm claims to have a conjugation yield of more than 95%.
Type of Product Manufactured	Highly Potent Active Pharmaceutical Ingredient Highly Potent Drug Formulation
Type of Highly Potent Finished Dosage Form	Capsules Tablets Liquids / Injectables
Type of Molecule Manufactured	Biologics Small Molecules
Additional Services Offered	In addition to manufacturing the HPAPIs and cytotoxic drugs, the company offers various other services, including: Formulation Development Stability Studies Analytical Testing Regulatory Support Fill / Finish Packaging

Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities:

Parameters	Details
Facility Locations	The company has nine facilities that offer HPAPI and cytotoxic drug manufacturing services: Dartford, Kent, UK Nottingham, East Midlands, UK Kansas City, Missouri, US Malvern, Pennsylvania, US San Diego, California, US Beinheim, Alsace, France Eberbach, Baden-Württemberg, Germany Greenville, US St. Petersburg, Florida, US
Facility Size	20,250 sq. ft. (Dartford Facility) 46,900 sq. ft. (Nottingham Facility) 421,665 sq. ft. (Kansas Facility) 84,000 sq. ft. (Malvern Facility) 68,000 sq. ft. (San Diego Facility) 78,100 sq. ft. (Beinheim Facility) 370,580 sq. ft. (Eberbach Facility) 333,000 sq. ft. (Greenville Facility) 500,000 sq. ft. (St. Petersburg Facility)
Scale of Operation	Preclinical Clinical Commercial
Regulatory Certification / Accreditation	ANVISA, EMA, FDA, MHLW

Key Developments:

• In October 2024, the company signed an agreement with Ardena, a CDMO, for offloading its oral solid dose manufacturing facility in Somerset, New Jersey.
• In February 2024, the company announced the expansion of its potent capsule filling capabilities for inhaled dry powders in its facilities in the US.

Further information related to this company and other HPAPI manufacturing companies is available in the full report.

CARBOGEN AMCIS, Having an Experience of 14 Years in the High Potency Domain, Claims to Have HPAPI Production Capacity of up to 8,000

CARBOGEN AMCIS, a subsidiary of Dishman Pharmaceuticals and Chemicals, offers a wide portfolio of drug development and commercialization services to various pharmaceutical and biopharmaceutical industries, across all stages of development. The company operates through eight sites located in China, France, the Netherlands, Switzerland and UK. Its integrated services for drug substances and drug products provide advanced solutions to support timely and safe drug development.

Given its experience in the high potency domain, the company offers ADC and bioconjugation services to small biotechnology, as well as large pharmaceutical companies. Further, the company strives to maintain the highest quality standards, provide exclusive custom synthesis and implement new technologies to support different types of chemistry.

HPAPI and Cytotoxic Drug Manufacturing Service Offerings:

Parameter	Description
Overview of HPAPI and Cytotoxic Drug Offerings	HPAPIs / Cytotoxic Drugs Production: CARBOGEN AMCIS states that its facilities dedicated to high potency and cytotoxic products are equipped with the required barrier isolation technology and Rapid Transfer Ports (RTPs), combined with pressure cascades, airlocks and access controls. According to the company, it is capable of handling substances within the OEL range of 0.01 µg / m3 - 1 µg / m3. Further, the different analytical techniques used for such compounds include Differential Scanning Calorimetry, High Performance Liquid Chromatography, Nuclear Magnetic Resonance and Ultraviolet spectroscopy. Conjugation Services: The state-of-the-art bioconjugation facility of the company supports the conceptualization and design of best linker and conjugation strategy for its clients. The ADC suite is equipped with suitable conjugation, analytical, purification and fill / finish capabilities.
Type of Product Manufactured	Highly Potent Active Pharmaceutical Ingredient Highly Potent Drug Formulation
Type of Highly Potent Finished Dosage Form	Liquids / Injectables
Type of Primary Packaging	Vials
Type of Molecule Manufactured	Biologics
Additional Services Offered	In addition to manufacturing, the HPAPIs and cytotoxic drugs, the company offers various other services, including: Process Development Formulation Development Stability Studies Analytical Testing Scale-Up Regulatory Support Fill / Finish Packaging

Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities:

Parameters	Details
Facility Locations	The company has six facilities that offer HPAPI and cytotoxic drug manufacturing services: Bubendorf, Basel-Country, Switzerland Hunzenschwil, Neuland, Switzerland Vionnaz, Valais, Switzerland Saint-Beauzire, France Shanghai, China Bavla, Gujarat, India
Facility Size	52,313 sq. ft. (Bubendorf Facility) 107,639 sq. ft. (Saint-Beauzire Facility) 430,556 sq. ft. (Shanghai Facility) 46,285 sq. ft. (Bavla Facility)
Scale of Operation	Preclinical Clinical Commercial
Regulatory Certification / Accreditation	EDQM, FDA, ISO, Kosher, OHSAS, TGA, WHO

Key Developments:

• In February 2025, the company announced the appointment of Stephan Fritschi as the new Chief Executive Officer, effective from April 2025.
• In January 2025, the company announced the completion of Swissmedic (the Swiss Agency for Therapeutic Products) inspection of its Vionnaz facility, in Switzerland, thereby renewing the site’s GMP certification and compliance with regulatory standards for HPAPI manufacturing.
• In March 2024, the company announced the successful completion of ANVISA (Brazilian Regulatory Authority Agency) audit, for its HPAPI manufacturing facility in Shanghai, China, thereby obtaining a GMP certificate from the auditor.

Further information related to this company and other HPAPI manufacturing companies is available in the full report.

Piramal Pharma Solutions Handles Derivatives or Analogs of Highly Potent Cytotoxic Agents Including Auristatin, Maytansinoids and Duocarmycins

Piramal Pharma Solutions is a contract development and manufacturing segment of the Piramal Group. The company specializes in the discovery, clinical development and commercial manufacturing of drug substances and drug products, including APIs, HPAPIs and antibody drug conjugates. The firm has been involved in the manufacturing of antibody drug conjugates for over 15 years and has developed an unparalleled track record in such operations. It is worth mentioning that the Grangemouth facility of the company has worked with more than 180 unique bioconjugate platforms.

Additionally, the company claims to have been successfully inspected by various regulatory bodies including Federal Commission for the Protection against Sanitary Risk, Health Canada (COFEPRIS), Ministry of Food and Drug Safety (MFDS), Pharmaceuticals and Medical Devices Agency (PMDA), Therapeutic Goods Administration (TGA) and the US Food and Drug Administration.

HPAPI and Cytotoxic Drug Manufacturing Service Offerings:

Parameter	Description
Overview of HPAPI and Cytotoxic Drug Offerings	HPAPIs / Cytotoxic Drugs Production: The company’s HPAPI manufacturing facilities have airlocks and barrier isolation systems, that are capable of safe handling compounds with OEL ≤ 0.02 µg/m3. Further, the Quality by Design (QbD) services of the company are aligned with the ICH Guidelines. In June 2019, the company expanded its HPAPI capabilities in its Riverview, US facility, through an investment of USD 10 million. Conjugation Services: The firm offers antibody drug conjugates contract development and manufacturing services through its facilities located in the UK and US. Further, it claims to have a batch success rate of 98%. All the suites of the company possess chromatographic purification capabilities and can handle volumes upto 1000L.
Type of Product Manufactured	Highly Potent Active Pharmaceutical Ingredient Highly Potent Drug Formulation
Type of Primary Packaging System	Blisters Vials
Type of Highly Potent Finished Dosage Form	Capsules Granules Liquids / Injectables Tablets Nanoparticles Liposomes
Type of Molecule Manufactured	Biologics Small Molecules
Additional Services Offered	In addition to manufacturing the HPAPIs and cytotoxic drugs, the company offers various other services, including: Process Development Formulation Development Stability Studies Analytical Testing Scale-Up Regulatory Support Fill / Finish Packaging

Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities:

Parameters	Details
Facility Locations	The company has six facilities that offer HPAPI and cytotoxic drug manufacturing services: Ahmedabad, Gujarat, India Grangemouth, Scotland, UK Lexington, Kentucky, US Riverview, Michigan, US Aurora, Ontario, Canada Sellersville, Pennsylvania, US
Facility Size	22,000 sq. ft. (Lexington Facility) 25,000 sq. ft. (Riverview Facility)
Scale of Operation	Preclinical Clinical Commercial
Regulatory Certification / Accreditation	EMA, FDA, PMDA, MPA, Taiwan GMP

Key Developments:

• In September 2024, the company announced a USD 80 million expansion plan for its facility in Lexington, Kentucky. With this expansion, the company aims to increase its production capacity by adding capabilities for the commercial scale sterile injectable contract manufacturing.
• In December 2023, the company announced the opening of its expanded antibody drug conjugates manufacturing facility in Grangemouth, Scotland, UK.
• In February 2023, the company initiated production of initial batches of high potency APIs in its new reactor suites in Riverview, US facility.

Further information related to this company and other HPAPI manufacturing companies is available in the full report.

Pfizer CenterOne Has the Capacity to Handle and Produce Highly Potent Drugs ranging from 100 g) to More Than 3 Metric Tons, Specifically for Small Molecule APIs

Pfizer CentreOne is a US based multi-specialty CMO focusing on API synthesis and sterile injectables fill-finish services. The company was launched by Pfizer in April 2016 after uniting Pfizer CentreSource (a global specialty API provider) and Hospira One 2 One (a sterile-injectables CMO). Additionally, the company specializes in the development and production of drug substances (small molecule APIs and large molecule biologics) as well as drug products (oral solid dosage forms and sterile injectables). Further, the company has fully segregated suites for non-potent and highly potent compounds, with OEL 1-5 engineering controls from 10,000 to 0.01 µg/m3. In addition, the team of chemists and engineers at the firm redesigns, optimizes, trouble-shoots and scales-up the manufacturing process of its clients.

HPAPI and Cytotoxic Drug Manufacturing Service Offerings:

Parameter	Description
Overview of HPAPI and Cytotoxic Drug Offerings	HPAPIs / Cytotoxic Drugs Production: Pfizer CentreOne provides contract manufacturing services for controlled substances, highly potent compounds, hormones and prostaglandins. Further, in October 2017 and March 2017, the company set up two new facilities in Nagoya, Japan and Newbridge, Ireland, respectively to offer in-country manufacturing of high potency oral solid dosage forms.
Type of Product Manufactured	Highly Potent Drug Formulation
Type of Highly Potent Finished Dosage Form	Capsules Liquids / Injectables Tablets
Type of Molecule Manufactured	Biologics Small Molecules
Additional Services Offered	In addition to manufacturing the HPAPIs and cytotoxic drugs, the company offers various other services, including: Process Development Formulation Development Stability Studies Analytical Testing Scale-Up Packaging

Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities:

Parameters	Details
Facility Locations	The company has four facilities that offer HPAPI and cytotoxic drug manufacturing services: Ascoli, Marche, Italy Freiburg, Baden-Wurttemberg, Germany Nagoya, Japan Newbridge, County Kildare, Ireland
Facility Size	1,614,585 sq. ft. (Freiburg facility) 968,751 sq. ft. (Nagoya Facility)
Scale of Operation	Preclinical Clinical Commercial
Regulatory Certification / Accreditation	EMA, FDA, GMP

Key Developments:

• In February 2024, the company acquired Immunogen and added flagship antibody drug conjugate, namely ELAHERE® (useful in treatment of platinum-resistant ovarian cancer) to its portfolio
• In 2023, the company won two awards at the 2023 Clinical Trials Arena Excellence Awards.
• In 2023, the company was presented with the ‘Green Pharmaceutical Award’ at the 2023 Green Awards.

Further information related to this company and other HPAPI manufacturing companies is available in the full report.

STA Pharmaceutical Provides One-Stop-Shop Solutions from Process R&D to Commercial Manufacturing of HPAPIs

STA Pharmaceutical, a WuXi AppTec company, is engaged in the research, development and manufacturing of small molecule APIs and finished dosage forms. Additionally, it offers efficient, flexible and superior quality solutions for integrated Chemical, Manufacturing and Controls (CMC) solutions, from preclinical to commercial uses.

Further, the company operates through eight sites, spread across California, Delaware, Jiangsu, Neuchatel and Shanghai, and has more than 1,000 research scientists for process development, optimization, scale-up and process validation. The firm strives to develop innovative medications, lower the cost of new drug development and shorten the drug development time in order to reach the market.

HPAPI and Cytotoxic Drug Manufacturing Service Offerings:

Parameter	Description
Overview of HPAPI and Cytotoxic Drug Offerings	HPAPIs / Cytotoxic Drugs Production: STA Pharmaceutical’ HPAPI facilities have an OEL of 0.01 µg/m³. Its capabilities include high potency milling through hammer mill, jet mill and pin mill. The highly potent manufacturing facilities of the company are equipped with reactors (size up to 3,000L), large scale preparative high performance liquid chromatography and lyophilizers (up to 10m2) to support large scale HPAPI manufacturing. Conjugation Services: The company develops and manufactures payloads for antibody drug conjugates. The firm is collaborating with the other WuXi AppTec sister companies in order to streamline the supply chain and all preclinical activities, thereby, simplifying the ADC development process.
Type of Product Manufactured	Highly Potent Active Pharmaceutical Ingredient Highly Potent Drug Formulation
Type of Primary Packaging System	Vials Prefilled Syringes
Type of Highly Potent Finished Dosage Form	Capsules Granules Liquids / Injectables Tablets
Type of Molecule Manufactured	Small Molecules
Additional Services Offered	In addition to manufacturing the HPAPIs and cytotoxic drugs, the company offers various other services, including: Process Development Formulation Development Analytical Testing Fill / Finish

Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities:

Parameters	Details
Facility Locations	The company has four facilities that offer HPAPI and cytotoxic drug manufacturing services: Changzhou, Jiangsu, China Jinshan, Shanghai, China Taixing, Jiangsu, China WuXi, Jiangsu, China
Facility Size	3,223,440 sq. ft. (Changzhou facility) 7,405,200 sq. ft. (Taixing facility)
Scale of Operation	Preclinical Clinical Commercial

Key Developments:

• In July 2023, the company launched its first fully automated, high potency sterile injectable manufacturing line at its drug product site located in Wuxi City, China.
• In 2023, the company received 2023 CDMO leadership award in recognition of capabilities and reliabilities.

Further information related to this company and other HPAPI manufacturing companies is available in the full report.

What About the Other HPAPI Manufacturing Companies?

The above presentation features the top 5 HPAPI manufacturing companies selected from a pool of over 140 firms that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources:

1. “Catalent Announces Addition of Potent Capsule Filling Capabilities for Inhaled Dry Powders at its Boston, MA USA Facility”
   https://www.catalent.com/catalent-news/catalent-announces-addition-of-potent-capsule-filling-capabilities-for-inhaled-dry-powders-at-its-boston-ma-usa-facility/
2. “Piramal Pharma Solutions Announces Production of First Batches at New API Facility in Riverview, Michigan”
   https://www.prnewswire.com/news-releases/piramal-pharma-solutions-announces-production-of-first-batches-at-new-api-facility-in-riverview-michigan-301747713.html
3. “WuXi STA Debuts Its First High Potency Sterile Injectable Manufacturing Line at Wuxi City Site”
   https://stapharma.com/en/news/newsroom/wuxi-sta-debuts-its-first-high-potency-sterile-injectable-manufacturing-line-at-wuxi-city-site/